

A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment

NCT06239116

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Rhythm Pharmaceuticals, Inc.
Enrollment	150 participants

Key Eligibility Criteria

Inclusion (19)

- Parts A and B:
- Male and female subjects in good health aged 18-55 years of age at Screening.
- Body mass index (BMI) ≤ 30 kg/m².
- Subjects who are medically healthy with normal or clinically insignificant screening results.
- Subjects must use a highly effective form of contraception and follow the study contraception requirements.

... and 14 more (see full listing online)

Exclusion (27)

- Parts A and B
- Any clinically significant abnormalities on screening laboratories or physical examination as determined by the Investigator.
- Active or history of any significant medical condition such as and including renal, hepatic, pulmonary, gastrointestinal, cardiovascular, genitourinary, endocrine, immunologic, metabolic, neurologic or hematological disease.
- Obesity due to genetic, syndromic, or endocrine etiologies.
- History of renal transplant, end stage renal disease.

... and 22 more (see full listing online)

Locations (7 total)

UAB Pediatric Endocrinology (Part C and Part D), Birmingham, Alabama, United States
Ann and Robert H. Lurie Children's Hospital of Chicago (Part C and Part D), Chicago, Illinois, United States
Boston Children's Hospital (Part C only), Boston, Massachusetts, United States
... and 4 more locations